Workflows

To identify the body of eligible literature across multiple databases before screening and synthesis.

To filter search results to relevant studies using independent reviewers.

To collect outcome data and assess study quality before quantitative synthesis.

To quantitatively assess the primary efficacy outcome across included studies.

To investigate why results differ across studies and to identify optimal stimulation parameters for each intervention where possible.

To test whether the synthesized results remain stable under alternative analytical assumptions or study subsets.

The review states that cell-type-specific genetic tools allow interrogation of neural circuits with increased precision.

The abstract states that functionally precise brain mapping requires anatomically tracing neural circuits.

The abstract states that functionally precise mapping requires monitoring activity patterns and lists multiple monitoring modalities.

The abstract states that manipulating neural activity is required to infer function.

This stage captures a broad initial literature set using structured query terms relevant to capsids, route, and biological context.

This stage narrows a very large initial search result into a tractable set of abstracts suitable for systematic review and translational synthesis.

Organizing findings by administration route supports translational interpretation of where different engineered capsids may be most useful.

This stage creates the draft genome assembly that all downstream annotation steps depend on.

This stage generates the structural gene annotation needed before functional annotation can be assigned.

This stage adds biological interpretation and external evidence support to predicted genes and proteins.

This stage evaluates the completeness of the produced genome resource.

This stage creates the NIR-responsive sustained-release therapeutic formulation.

This stage verifies that the intended formulation was formed and that PDGF-BB is associated with the nanosheets.

This stage tests whether the formulation solves the short half-life and rapid clearance problem motivating the study.

This stage checks whether the formulation is compatible with chondrogenic cells before or alongside in vivo efficacy testing.

This stage tests whether the controlled-release formulation translates into therapeutic benefit in vivo.

This stage is used to confirm pathway relevance beyond the mouse model and cultured cells.

This stage establishes how the two engineered strains perform under different nutrient conditions before downstream application testing.

This stage provides analytical and process readouts needed to compare strains and media over time.

This stage confirms growth behavior observed in the main cultivation comparison.

This stage evaluates whether the produced lipopeptides have practical biocontrol activity against soybean phytopathogens.

This stage tests whether the produced surfactin shows function relevant to enhanced oil recovery and related uses.

This stage adds structural and compositional detail to the production and application comparisons.

This stage defines the final analyzable cohort before measurement and modeling.

This stage generates the input labels and biomarker features required for downstream ML modeling.

This stage explores multiple model/task configurations to identify useful EV-based and multimodal classifiers.

This stage identifies the best-performing models and explains feature-stage relationships.

This stage identifies a donor-acceptor pair suitable for building red-shifted FRET biosensors.

This stage converts the selected fluorophore pair into a working biosensor backbone.

This stage checks whether the red-shifted backbone preserves performance relative to an established CFP/YFP PKA biosensor.

This stage tests whether the red-shifted design enables simultaneous use with standard CFP/YFP biosensors.

This stage tests whether the red-shifted biosensor can operate with a blue-light optogenetic actuator that would conflict with CFP/YFP biosensors.

This stage extends validation from in vitro demonstrations to living tissues in transgenic mice.

This stage creates the vesicular carrier component that packages IL-10 mRNA and adds cardiac-targeting peptide functionality before magnetic assembly.

This stage equips magnetic nanoparticles to bind CD63-positive vesicle components and target damaged myocardial tissue through MLC3 recognition.

This stage produces the final composite carrier that integrates vesicle targeting and magnetic localization functions.

This stage verifies that the intended functionalization and assembly steps succeeded before biological testing.

This stage checks whether the assembled carrier actually localizes to injured cardiac targets and improves delivery before therapeutic interpretation.

This stage validates whether targeted delivery translates into therapeutic benefit in myocardial infarction.

The review organizes integration strategies by the type of constraint they impose, indicating that early workflow logic is to narrow feasible model behavior using biologically motivated constraints.

The abstract identifies enzyme-constrained modelling as a practical workflow category for imposing capacity limits on fluxes.

The abstract presents thermodynamics as providing physical calibration and names thermodynamic embedding as a practical workflow.

The abstract explicitly states that fluxomics provides experimental calibration and names fluxomics-guided calibration as a practical workflow.

The abstract explicitly couples practical workflows with minimal reporting standards to ensure transparency and reproducibility.

The abstract identifies emerging translational pipelines that connect computational predictions to experimental validation.

This stage extracts the reusable core architecture from native systems before artificial pair reconstruction.

This stage converts isolated native cores into engineered RNA device pairs.

The stage exists to produce orthogonal and portable regulator pairs rather than only reconstructed native-like pairs.

This stage demonstrates that the designed RNA devices work as practical regulatory tools and support downstream circuit behaviors.

This stage generates antigen-binding sherpabodies that can serve as targeting modules for downstream CAR engineering.

This stage converts selected binders into functional T-cell receptor constructs for downstream testing.

This stage tests whether engineered SbCARs function specifically and kill target cells before in vivo evaluation.

This stage extends baseline CAR function into more advanced circuit behaviors enabled by sherpabody modularity and small size.

This stage tests whether SbCAR T cells retain antitumor function in vivo after in vitro characterization.

This stage captures the initial release event from producing cells.

This stage measures how secreted paracrine factors move through extracellular space after release.

This stage links extracellular paracrine factors to engagement of target cells.

This stage confirms that paracrine factor binding is associated with downstream signaling responses in target cells.

This stage creates the engineered T-cell product needed for downstream efficacy and safety testing.

This stage establishes whether the engineered T cells have measurable antitumor function against TNBC targets before in vivo evaluation.

This stage confirms that in vitro activity translates to antitumor efficacy in animal models, including orthotopic, metastatic, and patient-derived settings.

This stage tests whether antitumor activity can be achieved without damaging normal tissues that express TROP2.

This redesign stage addresses the safety failure of the direct TROP2 CAR-T approach while aiming to retain efficacy.

This stage tests whether the logic-gated redesign solves the key safety problem without sacrificing antitumor function.

This stage provides the actuation arm of all-optical electrophysiology.

This stage provides the sensing arm needed to analyze cardiac activity and arrhythmias.

The review identifies the merger of optogenetics and optical mapping as the key step that enables contactless actuation and sensing together.

The abstract uses ex vivo imaging and in vivo pacing as evidence that the field is narrowing the gap toward clinical use.

The review highlights motion tracking as reducing a key optical mapping limitation and computation as helping analyze complex data and optimize strategies.

The review frames implantable optoelectronic systems as a therapeutic endpoint enabled by hardware miniaturization and biocompatibility.

This stage identifies selective chemical matter against key endocannabinoid enzymes and establishes perturbation tools for downstream biology.

This stage refines and supports translational inhibitor development after initial probe-enabled discovery.

This stage adds spatial and cell type-specific context to enzyme activity beyond inhibitor discovery alone.

The review explicitly states this stage is needed because activity-based probes cannot capture transport, release, and uptake of signaling lipids in a spatiotemporally controlled manner.

This stage provides direct dynamic readout of endocannabinoid release across increasingly physiological systems.

This stage identifies a donor/acceptor pair suitable for building a red-shifted FRET biosensor.

This stage converts the selected fluorescent protein pair into a working biosensor backbone.

This stage checks whether the red-shifted backbone retains useful biosensor performance after engineering.

This stage confirms that the engineered spectral shift solves the intended compatibility problems in live-cell use cases.

This stage validates that the biosensor can function in living tissues in an animal context, extending beyond in vitro demonstrations.

The abstract explicitly states that opsin biophysical properties determine whether stimulation or silencing will be reliable and precise, and that spectral shifts can improve penetration and combinatorial use.

The review states that expression of the chosen optogenetic tool is required before optical control can be attempted in cardiac cells or whole systems.

Even with a suitable opsin and expression strategy, optical control depends on practical light delivery to the cardiac tissue.

The abstract presents these readouts as the means to confirm and monitor the effects of cardiac optogenetic stimulation.

The abstract states that the study used an in-silico library of CAR constructs as the starting point for the design campaign.

The abstract explicitly states that in vitro screening followed the in-silico library and enabled development of CARMSeD.

The abstract links predictive modeling to identification of optimized bispecific CAR T cells with superior persistence and anti-tumor efficacy.

The abstract states that the platform further improves durability by adding a PROTAC-based AKT3 degradation module.

The abstract describes extension of the strategy to a trispecific platform that remains effective in CD19/CD20-negative malignancies and across patient-derived leukemia samples and solid tumor models.

This stage creates the functional biosensor surface needed for analyte detection.

This stage quantifies whether the assembled biosensor performs adequately for Aβ42 and Aβ40 detection.

This stage checks whether the biosensor signal is affected by a related non-target biomarker.

This stage tests whether the biosensor retains utility in a more realistic biological sample matrix than buffer-only measurements.

The review states that mixotrophic cultivation is often preferred to maximize protein production and that light quality, carbon sources, and nitrogen availability direct metabolic fluxes toward protein biosynthesis.

The abstract identifies CRISPR/Cas9 as promising but still challenging and limited for enhancing microalgal protein production, while random mutagenesis is described as proven effective across multiple strains.

The abstract emphasizes drying, extrusion forming, and fermentation as downstream engineering approaches for improving whole-cell product properties.

The abstract states that extracted proteins broaden potential applications and that their quality is significantly affected by cell disruption/extraction, purification, and hydrolysis methods.

The abstract states that novel biorefinery strategies enhance economic viability by integrating value-added biomass utilization within a protein-first recovery scheme.

This stage creates the engineered CAR T-cell product needed for downstream expansion and testing.

This stage characterizes whether the engineered cells can be expanded to a viable product with the desired phenotype in serum-free media.

This stage confirms that the manufactured CAR T cells retain antigen-specific antitumor function.

This stage tests whether a simplified construct intended to enhance safety can still support CAR T-cell manufacturing outputs.

This stage identifies the better stable producer-cell-line background before committing to process optimization and scale-up.

This stage identifies the better production hardware platform after selecting the producer cell line.

This stage confirms that the selected process can be transferred to a larger manufacturing scale.

This stage checks that process optimization and scale-up preserve the intended functional output of the LV product.

This stage identifies which cannabinoid is the strongest antioxidant candidate before committing to formulation work.

This stage converts the selected antioxidant cannabinoid into a delivery format suitable for downstream physicochemical and diffusion testing.

This stage checks whether the liposomal formulation remains physically suitable and functionally active after loading CBN.

This stage provides an early-stage screen of whether the formulation improves mobility in a model relevant to dermal application goals.

This stage interprets whether the combined data justify positioning the formulation as a promising dermal antioxidant candidate.

This stage generates the plaque and control tissue inputs required for comparative multi-omics profiling.

This stage identifies proteins altered between injured and uninjured aortas.

This stage identifies metabolites altered in plaque tissue, including lipid components and pathway-linked metabolites.

This stage integrates protein and metabolite changes to infer correlated molecular signatures and implicated pathways.

The review describes PCR-based methods as an earlier molecular diagnostic stage for known polymorphisms.

Microarray genotyping and NGS are described as high-throughput approaches that broaden blood group variant detection.

The review states that integrating genomic data with serological testing improves blood group profiling accuracy and donor screening for rare antigens.

This stage establishes whether Gpr45 has a detectable role in energy balance before narrowing to specific cell types or brain regions.

This stage narrows the broad global phenotype to specific neuronal classes implicated in appetite regulation.

This stage tests whether the PVH is a major anatomical locus for the obesity and hyperphagia phenotype.

This stage directly tests whether activity of PVH Gpr45 neurons can drive or suppress feeding phenotypes beyond receptor deletion alone.

The abstract identifies multiple carrier classes as promising approaches to improve resveratrol delivery performance.

The review describes strategies to improve key formulation properties of existing nanoformulations.

The abstract explicitly states that in vivo testing is needed to avoid potential safety issues.

This stage creates the engineered primate model by introducing hM3Dq into the target brain region.

This stage noninvasively verifies that the chemogenetic receptor is expressed in vivo before downstream activation and behavioral interpretation.

This stage adds cellular confirmation beyond in vivo imaging.

This stage tests whether expressed DREADDs are functionally activatable by agonist administration.

This stage links chemogenetic activation to an observable behavioral output in freely moving marmosets.

This stage creates the physical scaffold architecture needed for controlled shape transformation while addressing transport limitations of dense hydrogels.

This stage establishes tunability and control over scaffold behavior before biological proof-of-concept testing.

The abstract indicates that cell compatibility is needed before using the constructs for tissue formation.

This stage provides the proof-of-concept biological application for the engineered scaffold platform.

This stage creates the sensing architecture needed to convert cTnI detection into intracellular signaling and gene-expression control.

This stage verifies that the receptor works in relevant mammalian cell contexts before building therapeutic output lines.

This stage converts the sensing module into a therapeutic closed-loop cell product.

This stage narrows multiple monoclonal lines to a lead clone with sensitivity matched to human AMI-relevant biomarker levels.

This stage confirms that the selected therapeutic clone performs the intended closed-loop function in a clot-lysis assay.

This stage establishes that lymphatic vessels are present in the decidua before downstream isolation and analysis of dLECs.

This stage generates the primary cell population needed for molecular and functional comparison between severe preeclampsia and control samples.

This stage confirms that the isolated cultured cells are decidual lymphatic endothelial cells before comparative profiling.

This stage identifies molecular programs altered in severe preeclampsia dLECs.

This stage tests whether molecular differences in severe preeclampsia dLECs correspond to impaired lymphatic endothelial function.

This stage connects impaired dLEC function in severe preeclampsia to specific immune-trafficking and signaling defects.

This stage reduces the search space to genes shared between PN phytochemical associations and HIV, creating a focused target set for downstream network analysis.

This stage prioritizes a smaller set of hub genes from the intersecting gene network for functional interpretation and docking.

This stage assigns biological meaning to the prioritized hub genes before or alongside docking-based target interaction analysis.

This stage evaluates which PN phytochemicals may interact strongly with prioritized HIV-relevant hub targets.

To define the candidate chemical components of the decoction for downstream target and mechanism analysis.

To define the disease-associated target space relevant to insomnia comorbid with depression.

To interpret the identified targets in terms of biological processes and pathways relevant to the disease context.

To prioritize a smaller set of important targets from the broader target landscape.

To test whether prioritized active ingredient-target pairs have plausible binding interactions in silico.

To create the therapeutic genetic payload used in the delivery system.

To provide lesion-targeting delivery of the recombinant plasmid.

To verify that the delivered plasmid can reach the nucleus and function after targeted delivery.

To confirm the mechanistic contribution of gas vesicles under ultrasound.

To test whether the engineered system produces therapeutic benefit in an animal atherosclerosis context.

This stage creates the synthetic transcriptomic inputs needed to profile compartment-specific responses in silico.

This stage converts synthetic transcriptomic outputs into a risk signal that can guide optimization.

This stage provides a predictive scoring function for candidate nanoparticle formulations.

This stage searches the nanoparticle design space to prioritize candidate formulations before experimental validation.

This stage establishes the perturbation and sampling framework needed to measure how cold stress responses change over time.

This stage captures phenotypic consequences of cold stress that can be compared with gene-expression changes.

This stage generates transcriptomic data for differential expression and pathway analysis.

This stage filters raw reads before downstream analysis to improve data quality.

This stage converts filtered sequencing data into interpretable gene and pathway changes associated with cold stress.

This stage creates the candidate design space for transcriptional control by specifying the trans-acting factor and cis-element combinations to be tested.

This stage narrows the design space to promoter configurations with better performance characteristics.

This stage provides functional evidence for the best-performing transcriptional designs.

This stage extends control beyond transcription to translation and tests whether light can repress protein synthesis without altering mRNA expression.

This stage prepares the EV-enriched input required for downstream proteomic profiling.

This stage generates the broad protein-level dataset used to compare hepatic steatosis groups.

This stage narrows the measured EV proteome to proteins most strongly associated with hepatic steatosis status.

This stage interprets the differential proteins biologically and tests whether signatures vary across clinically relevant subgroups.

This stage provides orthogonal evidence from liver transcriptomic datasets to prioritize EV protein candidates for future validation.

The review places prevention first in line with WHO outbreak-control priorities.

The review identifies early detection as a core outbreak-control strategy and maps diagnostic nanotechnologies to that need.

The review places treatment after prevention and diagnosis as the third major strategy.

To identify the available TPS literature across databases before screening and synthesis.

To narrow the search results to studies eligible for inclusion in the review.

To collect outcome and safety data in a structured way and assess study quality before interpretation.

To evaluate internal validity using tools matched to study design before drawing conclusions about TPS effects.

To summarize whether TPS appears promising while explicitly accounting for study limitations.

The abstract states that the indicators were developed through directed evolution in Escherichia coli as an initial engineering stage.

The abstract explicitly states that optimization in mammalian cells followed directed evolution in E. coli.

The abstract reports affinities and localization-specific responses in HEK293FT cells before broader biological deployment.

The abstract describes deployment of the indicators in progressively more intact neural systems to demonstrate real-time potassium imaging capability.

The abstract states that molecular dynamics simulations provided insights into potassium-binding mechanisms and distinct binding pockets.

To identify candidate STING ligands before experimental testing.

To experimentally confirm that the selected compound directly interacts with STING.

To validate that the observed binding depends on a Teniposide-sensitive STING interface.

To characterize how Teniposide may bind STING after direct interaction was established experimentally.

To show that direct binding corresponds to pathway activation and to distinguish the mechanism from canonical upstream dsDNA-sensor activation.

This stage establishes the core rescue phenotype that motivates subsequent mechanistic dissection.

This stage connects the rescue phenotype to candidate neural substrates before causal perturbation.

This stage tests whether the identified circuit can reproduce rescue-associated outcomes.

This stage checks whether the activation effects depend on oxytocin receptor signaling in the VTA.

This stage complements sufficiency testing by asking whether loss of circuit function opposes rescue-associated outcomes.

This stage extends the circuit and behavioral findings to downstream molecular signatures in the nucleus accumbens.

This stage identifies candidate genes associated with leaf senescence before targeted validation and functional testing.

This stage confirms that transcriptome-nominated NAC candidates show expression patterns consistent with senescence association.

This stage tests whether prioritized NAC candidates causally promote or delay senescence when increased or reduced in expression.

This stage tests whether the senescence-promoting role of the candidate NAC genes extends to ABA- and darkness-associated stress contexts.

This stage compares available contrast formulations to establish whether nanoscale GVs can image the vascular wall and whether PEG modification improves persistence.

This stage establishes that CXCR4 is present in plaques and low in normal vessels, supporting the rationale for a CXCR4-targeted probe.

This stage tests whether adding CXCR4 targeting translates from biomarker rationale into measurable cell binding and stronger plaque imaging in animals.

This stage checks whether the targeted vesicles physically localize within vulnerable plaques and whether the formulations appear safe by the reported assays.

This stage generates the FPV VP2 material needed to form the vaccine candidate before characterization and animal testing.

This stage verifies that the expressed and purified VP2 formed virus-like particles before proceeding to animal immunization.

This stage tests whether the VLP vaccine induces measurable antibody responses in the target animal species before challenge.

This stage confirms whether vaccination translates into protection against virulent FPV infection in cats.

This stage exists to augment available wastewater measurements before predictive modeling.

This stage performs the main predictive task and derives removal-efficiency estimates from estimated viral concentrations.

This stage confirms whether the framework remains effective on unseen wastewater matrices and across regional settings.

This stage establishes the core inducible CRISPR systems needed for downstream functional and therapeutic testing.

This stage verifies that the engineered ultrasound-inducible tools perform the intended regulatory functions before therapeutic deployment.

This stage tests whether the genomic intervention creates a therapeutically useful tumour state for downstream cell therapy.

This stage validates that the inducible CRISPR system can be delivered in vivo and used to create localized tumour-cell training centers for downstream immunotherapy.

To create a versatile screening system in Escherichia coli for rapid anti-CRISPR characterization and Acr-based technology development.

To identify new anti-CRISPR proteins using the established PICI system.

To convert an AcrIIA4-derived scaffold into optogenetically controllable anti-CRISPR tools.

To confirm that OPERA4 functions as a light-controllable anti-CRISPR tool in both prokaryotic and human-cell settings.